Saturday 17 October 2026 Export ACAD’s income statement to Excel — free account

ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

19.12 0.59 −2.99%

Follow ACAD

Alert me

Market cap: $3.4B
P/E: 8.5×
Fwd P/E: 55.6×
Dividend yield: —
F-score: 6/9
Altman Z: 7.90
Beneish M: −0.89
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 3.40

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	3	—	—	1	5	2	3	1	1	1	—	—

Insider Ownership 0.91%

Capital & Financial Ratios $m

Market Cap 3,400.00

Revenue 1,138.64

Net Income 380.48

Free Cash Flow 145.63

Net Debt (956.47)

Current Ratio 3.39

Debt/Equity 0.00

P/E ratio 8.50

Fwd P/E 55.60

P/S ratio 2.88

P/B ratio 2.51

Past 5Y EPS Growth —

This Y EPS Growth (72.90%)

Next Y EPS Growth 50.50%

Next Y revenue growth 18.71%

Next 5Y EPS Growth (12.31%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.47%

10-year low 10-year high

P/B against its own 10 years 0.07%

10-year low 10-year high

EV/Sales against its own 10 years 1.55%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	439	756	820	956
Receivables	102	105	148	166
Inventory	36	22	35	32
Other	—	—	—	—
	616	938	1,062	1,225

	2023	2024	2025	Q'26
Payables	18	16	11	45
ST’ Debt	—	—	—	—
Other	—	—	—	—
	254	395	277	361

Compound Annual Growth %

	10y	5y	3y
Sales	165.75%	19.39%	27.48%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	19.91%	14.38%	45.26%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	268	308	—	—	—
’25	244	265	279	284	1,072
’24	206	242	250	260	958
’23	118	165	212	231	726
’22	115	135	131	136	517
’21	107	115	132	131	484
’20	90	110	121	121	442

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	34	101	—	—	—
’25	20	64	74	(49)	110
’24	29	25	63	40	158
’23	(18)	8	(59)	85	17
’22	(76)	(13)	(1)	(24)	(114)
’21	(60)	(25)	(17)	(23)	(126)
’20	(49)	(37)	(23)	(27)	(136)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	29	96	—	—	—
’25	(79)	64	(25)	(53)	105
’24	29	25	63	40	157
’23	(18)	(32)	(59)	85	(23)
’22	(76)	(13)	(1)	(24)	(114)
’21	(61)	(25)	(17)	(23)	(127)
’20	(50)	(40)	(25)	(29)	(144)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.02	0.18	—	—	—
’25	0.11	0.16	0.42	1.60	2.30
’24	0.10	0.20	0.20	0.86	1.36
’23	(0.27)	0.01	(0.40)	0.28	(0.37)
’22	(0.70)	(0.21)	(0.17)	(0.26)	(1.34)
’21	(0.42)	(0.27)	(0.09)	(0.27)	(1.05)
’20	(0.57)	(0.27)	(0.54)	(0.42)	(1.79)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	16.64	25.06	12.77	15.73	30.02	15.68	12.24	15.77	14.15	13.40	Analyst estimates 2026–2028 Powerpack
	High	42.49	41.20	32.99	53.70	58.72	55.85	28.06	33.99	31.82	28.35
People
People	Employees	370	425	430	503	601	514	513	598	654	798
	Revenue/emp, $m	0.05	0.29	0.52	0.67	0.74	0.94	1.01	1.21	1.46	1.34
Income, $m
Income, $m	Revenue	17	125	224	339	442	484	517	726	958	1,072
	Gross margin, %	82.26	92.73	94.47	96.65	97.69	96.05	98.03	94.27	91.46	91.69
	EBT	(270)	(288)	(244)	(234)	(281)	(168)	(213)	(51)	258	139
	EBT margin, %	(1,558.20)	(230.81)	(108.99)	(69.12)	(63.60)	(34.60)	(41.27)	(7.03)	26.94	12.96
	Net income	(271)	(289)	(245)	(235)	(282)	(168)	(216)	(61)	226	391
	Depreciation	2	2	2	(1)	4	6	(1)	(2)	7	6
Per share, $
Per share, $	Revenue	0.15	1.02	1.77	2.30	2.81	3.02	3.20	4.43	5.78	6.36
	Earnings	(2.34)	(2.36)	(1.94)	(1.60)	(1.79)	(1.05)	(1.34)	(0.37)	1.37	2.32
	Cash flow	(1.80)	(1.78)	(1.32)	(1.03)	(0.87)	(0.78)	(0.71)	0.10	0.95	0.65
	Capex	(0.08)	(0.01)	(0.02)	(0.01)	(0.05)	(0.01)	0.00	(0.24)	0.00	(0.03)
	Free cash flow	(1.88)	(1.78)	(1.34)	(1.03)	(0.91)	(0.79)	(0.71)	(0.14)	0.95	0.62
	Book value	4.47	2.73	3.78	4.75	3.99	3.37	2.48	2.64	4.42	7.29
	Shares, m	116	123	127	147	157	160	162	164	166	168
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	13.49	11.51
	P/S	192.33	29.87	9.15	18.57	19.04	7.74	5.10	6.96	3.17	4.20
	P/B	6.43	11.13	4.27	9.01	13.41	6.93	6.59	11.71	4.15	3.66
	EV/Sales	161.81	27.14	7.03	16.52	17.61	6.66	4.30	6.36	2.39	3.43
	EV/FCF	(13.36)	(15.51)	(9.28)	(36.78)	(54.11)	(25.44)	(19.30)	(197.73)	19.51	(39.55)
Cash, $m
Cash, $m	Operating cash flow	(208)	(218)	(167)	(151)	(136)	(126)	(114)	17	158	110
	Capex	(10)	(1)	(2)	(1)	(8)	(1)	—	(40)	(1)	(5)
	Free cash flow	(218)	(219)	(170)	(152)	(144)	(127)	(114)	(23)	157	105
Balance, $m
Balance, $m	Working capital	505	324	467	685	612	522	382	362	543	785
	Total debt	0	—	—	6	44	56	53	—	—	—
	Net debt	(529)	(341)	(474)	(697)	(632)	(521)	(417)	(439)	(756)	(820)
	Shareholders’ equity	518	335	479	699	627	541	400	432	733	1,227
Returns, %
Returns, %	ROA	(69.32)	(61.21)	(53.03)	(35.55)	(35.97)	(22.64)	(33.54)	(9.17)	23.39	28.42
	ROIC	0.00	0.00	(2,782.02)	(9,032.28)	0.00	(527.66)	0.00	0.00	0.00	16.07
	ROE	(75.58)	(67.80)	(60.22)	(39.93)	(42.47)	(28.75)	(45.89)	(14.73)	38.89	39.89

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
TNGX Tango Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−4.58% (below 0%: shrinking)	0.00%	0.00%	Compare
RLAY Relay Therapeutics, Inc.	$3.8B	— (loss-making)	— (loss-making)	−95.44% (below 0%: shrinking)	n/m	+2.13% (above 0%: growing)	100.00%	(25,949.71%)	Compare
ARQT Arcutis Biotherapeutics, Inc.	$3.7B	131×	196×	+59.33% (above 0%: growing)	n/m	+227.96% (above 0%: growing)	91.58%	12.65%	Compare
TLX Telix Pharmaceuticals Limited	$3.6B	—	—	—	—	−44.78% (below 0%: shrinking)	—	—	Compare
TARS Tarsus Pharmaceuticals, Inc.	$3.5B	— (loss-making)	— (loss-making)	+69.41% (above 0%: growing)	n/m	+288.08% (above 0%: growing)	93.03%	(11.45%)	Compare
VKTX Viking Therapeutics, Inc.	$3.5B	— (loss-making)	—	—	n/m	−165.98% (below 0%: shrinking)	0.00%	0.00%	Compare
ACAD ACADIA Pharmaceuticals Inc.	$3.4B	8.5×	55.6×	+16.40% (above 0%: growing)	+12.50% (above 0%: growing)	+50.32% (above 0%: growing)	90.81%	12.29%
XENE Xenon Pharmaceuticals Inc.	$3.3B	— (loss-making)	— (loss-making)	+100.70% (above 0%: growing)	n/m	−48.57% (below 0%: shrinking)	100.00%	0.00%	Compare
IDYA IDEAYA Biosciences, Inc.	$3.3B	— (loss-making)	— (loss-making)	+125.77% (above 0%: growing)	n/m	−41.09% (below 0%: shrinking)	100.00%	(1,380.73%)	Compare
Median of peers	$3.6B	—	—	+64.37%	—	−22.83%	93.03%	0.00%

All 614 Biotechnology stocks →

ACADIA Pharmaceuticals Inc. (ACAD) key facts

Strength: ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.
ACADIA Pharmaceuticals Inc. (ACAD) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ACAD traded at $19.12, a market capitalization of $3.4 billion.
Return on equity was 39.9% and debt-to-equity 0.00.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 7.90 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.